Alphatec Stock Price, News & Analysis (NASDAQ:ATEC)

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alphatec in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ATEC shares.
View ATEC analyst ratings or view top-rated stocks.

7 brokers have issued 1-year price targets for Alphatec's stock. Their ATEC share price targets range from $16.00 to $32.00. On average, they predict the company's stock price to reach $21.86 in the next year. This suggests a possible upside of 71.4% from the stock's current price.
View analysts price targets for ATEC or view top-rated stocks among Wall Street analysts.

Alphatec's stock was trading at $12.35 on January 1st, 2023. Since then, ATEC stock has increased by 3.2% and is now trading at $12.75.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our ATEC earnings forecast.

Alphatec Holdings, Inc. (NASDAQ:ATEC) announced its quarterly earnings results on Monday, November, 6th. The medical technology company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.30) by $0.05. The medical technology company earned $118.26 million during the quarter, compared to analyst estimates of $115.30 million.

ETFs with the largest weight of Alphatec (NASDAQ:ATEC) stock in their portfolio include Jacob Forward ETF (JFWD), Innovator IBD 50 ETF (FFTY), SPDR S&P Health Care Equipment ETF (XHE) and Invesco Dorsey Wright Healthcare Momentum ETF (PTH).First Trust Nasdaq Lux Digital Health Solutions ETF (EKG).

Alphatec updated its third quarter 2023 earnings guidance on Monday, October, 16th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $117.70 million-$118.50 million, compared to the consensus revenue estimate of $111.78 million.

19 employees have rated Alphatec Chief Executive Officer Pat Miles on Glassdoor.com. Pat Miles has an approval rating of 72% among the company's employees. 63.0% of employees surveyed would recommend working at Alphatec to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Alphatec investors own include Macrocure Ltd. - Ordinary Share (MCUR), LinnCo (LNCOQ), California Resources (CRC), Sorrento Therapeutics (SRNE), Catalyst Pharmaceuticals (CPRX), (GBSN) (GBSN), Idera Pharmaceuticals (IDRA), Athersys (ATHX), Anavex Life Sciences (AVXL) and BioCryst Pharmaceuticals (BCRX).

Alphatec's stock is owned by a number of institutional and retail investors. Top institutional shareholders include American Century Companies Inc. (1.95%), Fred Alger Management LLC (1.71%), Assenagon Asset Management S.A. (1.32%), Royal Bank of Canada (1.14%), abrdn plc (1.15%) and New York State Common Retirement Fund (0.73%). Insiders that own company stock include Craig E Hunsaker, David H Mowry, David M Demski, David R Pelizzon, David Sponsel, Elizabeth Ann Altman, Evan Bakst, James L L Tullis, James L L Tullis, Jason Hochberg, Jeffrey G Black, Jennifer N Pritzker, Jennifer N Pritzker, John Todd Koning, L-5 Healthcare Partners, Llc, Mortimer Berkowitz III, Patrick Miles, Paul Segal and Scott Lish.
View institutional ownership trends.

Shares of ATEC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.